SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : 2008 Biotech Stock Picking for Charity -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (117)1/19/2008 9:29:30 AM
From: idos  Respond to of 322
 
Not ruling out multiple settlements rather saying there are difficulties. Bear in mind that the FTC may challenge the Provigil settlements and reverse the agreement.
Settlement of Xopenex with all three filers will probably trigger FTC review.

Xopenex patent expiry- Mar, 2021 but I think it's a formulation patents extend and not strong enough to protect from generics.
The 30-month stay expiry for the first - Mar 08. I expect a settlement at least with Breath or at-risk launch.

Lunesta has indeed short patent life - expiry Aug, 2012 (will probably get extension). It is very likely to be challenged by the end of 08.



To: rkrw who wrote (117)1/29/2008 2:19:23 PM
From: idos  Read Replies (1) | Respond to of 322
 
On the positive side, Adams did prevent genericization of Niaspan by settling with Barr when he worked for Kos.

.



To: rkrw who wrote (117)2/14/2008 8:22:24 AM
From: idos  Read Replies (1) | Respond to of 322
 
FTC sues CEPH over the Provigil settlements:

ftc.gov


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News